Abstract
Background: Depression is the leading cause of disability in individuals aged 15-44, resulting in about 400 million disability days per year. The total economic burden is estimated to be $26.1 billion in direct medical costs. Electroconvulsive therapy (ECT) is the gold-standard treatment for major depressive disorder (MDD) and is currently regarded as the most effective treatment for depression, but patients commonly use concurrent medication treatment. Bupropion is a common atypical antidepressant that can affect seizure parameters according to a recent retrospective chart review, and physiologic parameters may be affected as well.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
